Nicotine inhibits Fc epsilon RI-induced cysteinyl leukotrienes and cytokine production without affecting mast cell degranulation through alpha 7/alpha 9/alpha 10-nicotinic receptors.
Smokers are less likely to develop some inflammatory and allergic diseases. In Brown-Norway rats, nicotine inhibits several parameters of allergic asthma, including the production of Th2 cytokines and the cysteinyl leukotriene LTC(4). Cysteinyl leukotrienes are primarily produced by mast cells, and these cells play a central role in allergic asthma. Mast cells express a high-affinity receptor for IgE (FcepsilonRI). Following its cross-linking, cells degranulate and release preformed inflammatory mediators (early phase) and synthesize and secrete cytokines/chemokines and leukotrienes (late phase). The mechanism by which nicotine modulates mast cell activation is unclear. Using alpha-bungarotoxin binding and quantitative PCR and PCR product sequencing, we showed that the rat mast/basophil cell line RBL-2H3 expresses nicotinic acetylcholine receptors (nAChRs) alpha7, alpha9, and alpha10; exposure to exceedingly low concentrations of nicotine (nanomolar), but not the biologically inactive metabolite cotinine, for > or = 8 h suppressed the late phase (leukotriene/cytokine production) but not degranulation (histamine and hexosaminidase release). These effects were unrelated to those of nicotine on intracellular free calcium concentration but were causally associated with the inhibition of cytosolic phospholipase A(2) activity and the PI3K/ERK/NF-kappaB pathway, including phosphorylation of Akt and ERK and nuclear translocation of NF-kappaB. The suppressive effect of nicotine on the late-phase response was blocked by the alpha7/alpha9-nAChR antagonists methyllycaconitine and alpha-bungarotoxin, as well as by small interfering RNA knockdown of alpha7-, alpha9-, or alpha10-nAChRs, suggesting a functional interaction between alpha7-, alpha9-, and alpha10-nAChRs that might explain the response of RBL cells to nanomolar concentrations of nicotine. This "hybrid" receptor might serve as a target for novel antiallergic/antiasthmatic therapies.
Mishra
Neerad C
NC
Immunology and Asthma Division, Lovelace Respiratory Research Institute, Albuquerque, NM 87108, USA.
Rir-sima-ah
Jules
J
Boyd
R Thomas
RT
Singh
Shashi P
SP
Gundavarapu
Sravanthi
S
Langley
Raymond J
RJ
Razani-Boroujerdi
Seddigheh
S
Sopori
Mohan L
ML
D000818:Animals; D001491:Basophils / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D015550:Cell Degranulation / Q000187:drug effects / Q000276:immunology*; D045744:Cell Line, Tumor; D003545:Cysteine / Q000037:antagonists & inhibitors* / Q000096:biosynthesis; D016207:Cytokines / Q000037:antagonists & inhibitors* / Q000096:biosynthesis; D003600:Cytosol / Q000187:drug effects / Q000201:enzymology / Q000276:immunology; D015536:Down-Regulation / Q000187:drug effects / Q000276:immunology; D015289:Leukotrienes / Q000096:biosynthesis; D020935:MAP Kinase Signaling System / Q000187:drug effects / Q000276:immunology; D008407:Mast Cells / Q000187:drug effects / Q000276:immunology / Q000378:metabolism*; D009538:Nicotine / Q000494:pharmacology*; D064801:Phospholipase A2 Inhibitors; D054467:Phospholipases A2 / Q000502:physiology; D051381:Rats; D011914:Rats, Inbred BN; D017455:Receptors, IgE / Q000037:antagonists & inhibitors* / Q000502:physiology; D011978:Receptors, Nicotinic / Q000502:physiology*; D014028:Tobacco Smoke Pollution / Q000009:adverse effects; D064569:alpha7 Nicotinic Acetylcholine Receptor
C470699:Chrna10 protein, rat; C579165:Chrna7 protein, rat; C498541:Chrna9 protein, rat; D016207:Cytokines; D015289:Leukotrienes; D064801:Phospholipase A2 Inhibitors; D017455:Receptors, IgE; D011978:Receptors, Nicotinic; D014028:Tobacco Smoke Pollution; D064569:alpha7 Nicotinic Acetylcholine Receptor; C112381:cysteinyl-leukotriene; D009538:Nicotine; D054467:Phospholipases A2; D003545:Cysteine